Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2

Status

Completed 69Terminated 20Recruiting 10Active not recruiting 7Unknown 5Withdrawn 2Suspended 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Gastrointestinal 2Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 21Prostatic Neoplasms 17Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 9Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Recurrence 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 26Cyclophosphamide 20Nivolumab 14Doxorubicin 13Surveys and Questionnaires 9Exercise 9Carboplatin 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Paclitaxel 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Pemetrexed 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × Docetaxel × Clear all
NCT03505320 2026-04-03

ILUSTRO

Astellas Pharma Inc

Phase 2 Active not recruiting
143 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Tesaro, Inc.

Phase 1 Active not recruiting
463 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

AbbVie

Phase 2 Active not recruiting
150 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

NCT04721015 2025-07-03

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

AbbVie

Phase 1 Active not recruiting
81 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Columbia University

Phase 2 Active not recruiting
26 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00798070 2024-12-18

PANTHER

Karolinska University Hospital

Phase 3 Active not recruiting
2,017 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT01957436 2024-11-12

PEACE1

UNICANCER

Phase 3 Active not recruiting
1,173 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡